Diabetes mellitus is a chronic metabolic disorder that involves not only impaired glucose metabolism but also the development of secondary psychoemotional disturbances, including increased anxiety. Recently, growing attention has been paid to the role of the gut microbiota and the «gut–brain axis» in the pathogenesis of neurological complications of diabetes. The aim of this study was to evaluate the effect of a probiotic microbial consortium composed of strains of Lactobacillus spp., Enterococcus faecium, and Brettanomyces bruxellensis on the anxiety level of rats with alloxan-induced diabetes mellitus. The diabetic model was reproduced by intraperitoneal administration of alloxan. Anxiety levels were assessed using the elevated plus maze behavioral test on days 1, 7, 14, and 21 after induction of alloxan-induced diabetes. The anxiety index was calculated based on the time the animals spent in the open arms of the maze. The obtained results demonstrated that in the diabetic model group, the anxiety index was significantly elevated at all observation points compared to the control group, indicating the development of a sustained anxiety-like state. Administration of the probiotic microbial consortium to diabetic rats led to a decrease in anxiety index values across all time points compared to the untreated diabetic group, suggesting partial recovery of emotional status. These findings imply that the probiotic microbial consortium may possess anxiolytic properties mediated through anti-inflammatory effects, correction of microbial dysbiosis, and restoration of gut–brain axis functionality. Thus, the probiotic microbial consortium can be considered a promising tool for the complex correction of psychoemotional disorders in insulin-deficient forms of diabetes, as well as a preventive approach to anxiety-related conditions associated with neuroinflammation and microbiota imbalance.
probiotic microbial consortium, alloxan-induced diabetes mellitus, anxiety index, rats.
1. Strachan M. W. J. Cognitive function, depression, and quality of life in patients with type 1 diabetes / M. W. J. Strachan I. J., Deary, F. M. E. Ewing, B. M. Frier // Diabetes Care. – 2011. – Vol. 24, № 4. – P. 775–778.
2. Yarmolyuk N. S. Vliyanie probioticheskogo mikrobnogo konsorciuma na povedencheskie reakcii krys s alloksaninducirovannym saharnym diabetom / N. S. Yarmolyuk, E. R. Dzheldubaeva,
3. Yiğit S. Effects of diabetes mellitus on anxiety and depression levels / S. Yiğit, E. Yiğit, M. Bozkurt // Neurosciences (Riyadh). – 2019. – Vol. 24, № 2. – P. 103–107.
4. Cryan J. F. Mind-altering microorganisms: the impact of the gut microbiota on brain and behavior / J. F. Cryan, T. G. Dinan // Nature Reviews Neuroscience. – 2012. – Vol. 13. – P. 701–712.
5. Halmos T. Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome / T. Halmos, I. Suba // Orv Hetil. – 2016. – V. 157, № 5. – P. 13–22.
6. Zhang L. Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications / L. Zhang, J. Chu, W. Hao [et al.] // Mediators Inflamm. – 2021. – V. 7. – P. 16–18.
7. Dinan T. G., Gut–brain axis in 2016: Brain–gut–microbiota axis — mood, metabolism and behaviour / T. G. Dinan, J. F. Cryan // Nature Reviews Gastroenterology & Hepatology. – 2017. – V. 14. – P. 69–70.
8. Garganeeva N. P. Psihosocial'nye faktory, trevozhnye i depressivnye rasstroystva u pacientov s ishemicheskoy bolezn'yu serdca: problemy komorbidnosti i prognozirovaniya
9. Petrlova B. Depressive disorders and the matabolic syndrome of the insulin resistance / B. Petrlova, H. Rosolva, Z Al // Semin. – 2004. – V. 4. – P. 161–165.
10. Skilton M. R., Associations between anxiety, depression, and the metabolic syndrome / M. R. Skilton, P. Moulin, J. L. Terra [et al.] // Biol. Psychiatry. – 2007. – V. 62. – P. 251–1257.
11. Bjorntorp P. Metabolic Implications of Body Fat Distribution / P. Bjorntorp // Diabetes Care. – 1991. – V. 14, № 12. – P. 1132–1143.
12. Boyle S. Depressive Symptoms, Race, and Glucose Concentrations / S. Boyle R. Surwit [ et al.] // Diabetes Care. – 2007. – V. 3. – P. 567–578.
13. Ghahremani Z. The protective effect of probiotic supplementation on depression, anxiety and stress in diabetes mellitus patients. A randomized double-blind clinical trial / Z. Ghahremani, M. Shabani,
14. Sanchez M. Probiotics and prebiotics in the management of depressive symptoms: A systematic review / M. Sanchez, C. Darimont, V. Drapeau // Nutrients. – 2017. – V. 9, № 11. – P. 1220.
15. Husainov D. R. Shestidnevnaya dinamika indeksa trevozhnosti vysokotrevozhnyh krys-samok pri blokade MAO-V / D. R Husainov, A. N. Luk'yanceva, N. S. Tribrat [i dr.] // Siberian Journal of Life Sciences
16. Chuyan E. N. Vliyanie millimetrovyh voln neteplovoy intensivnosti na razvitie gipokineticheskogo stressa u krys s razlichnymi individual'nymi osobennostyami: Avtoref. dis. kand. biol. nauk.
17. Danilova I. G. Sposob modelirovaniya alloksanovogo diabeta / I. G. Danilova, I. F. Gette: Patent na izobretenie № 2534411; zayavl. 27.11.2014; opubl. 27.11.2014. – Byul. № 33.
18. Rukovodstvo po eksperimental'nomu (doklinicheskomu) izucheniyu novyh farmakologicheskih veschestv/Pod obschey red. chlen-korr. RAMN, prof. R.U. Habrieva. – 2-izd.,pererab. i dop.–
19. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas / Szkudelski T. // Physiological Research. – 2001. – V. 50. – P. 537–546.
20. Izuno S. Role of Gut Microbiota in the Pathophysiology of Stress-Related Disorders: Evidence from Neuroimaging Studies / S. Izuno, K. Yoshihara, N. Sudo // Ann Nutr Metab. – 2021. – V. 77. – P. 4–10.
21. Osadchiy V. The Gut-Brain Axis and the Microbiome: Mechanisms and Clinical Implications / V. Osadchiy, C. R. Martin, E. A. Mayer // Clin Gastroenterol Hepatol. – 2019. –Vol. 17, № 2. – P. 322–332.
22. Sanchez M. Probiotics and prebiotics in the management of depressive symptoms: A systematic review / M. Sanchez, C. Darimont, V. Drapeau // Nutrients. – 2017. – V. 9, № 11. – P. 1220.
